Research & Literature

Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Miyazaki K, Kawai S, Suzuki K

International journal of hematology 2015; (102(3)):289-95 doi:10.1007/s12185-015-1827-8.

[Light Chain Amyloidosis: an Update for Treatment].

Shen KN, Li J

Zhongguo shi yan xue ye xue za zhi 2015; (23(3)):910-4 doi:10.7534/j.issn.1009-2137.2015.03.059.

Renal AH Amyloidosis Associated With a Truncated Immunoglobulin Heavy Chain Undetectable by Immunostaining.

Manabe S, Hatano M, Yazaki M, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(6)):1095-100.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, et al.

Blood 2015; (126(20)):2345-7 doi:10.1182/blood-2015-08-662726.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Dejoie T, Attal M, Moreau P, et al.

Haematologica 2016; (101(3)):356-62 doi:10.3324/haematol.2015.126797.

Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.

Muchtar E, Buadi FK, Dispenzieri A, Gertz MA

Acta haematologica 2016; (135(3)):172-90 doi:10.1159/000443200.

Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.

Mollee P, Merlini G

Clinical chemistry and laboratory medicine 2016; (54(6)):921-7.

Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.

Wang Y, Xu P, Chen Y, et al.

Molecular and clinical oncology 2016; (4(1)):107-113 doi:10.3892/mco.2015.658.

Primary Systemic Amyloidosis with Unusual Dermatological Manifestations: A Rare Case Report.

Vyas K, Morgaonkar M, Gupta S, Jain SK

Indian journal of dermatology 2016; (61(2)):216-8 doi:10.4103/0019-5154.177767.

LC-MS/MS analysis of steroids in the clinical laboratory.

Keevil BG

Clinical biochemistry 2016; (49(13-14)):989-97.

Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine.

Okamoto LE, Diedrich A, Baudenbacher FJ, et al.

Hypertension (Dallas, Tex. : 1979) 2016; (68(2)):418-26 doi:10.1161/HYPERTENSIONAHA.116.07199.

Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies:  High False-Positive Rate.

Singh G

American journal of clinical pathology 2016; (146(2)):207-14 doi:10.1093/ajcp/aqw099.

Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2016; (91(9)):947-56 doi:10.1002/ajh.24433.

Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.

Muchtar E, Derudas D, Mauermann M, et al.

Mayo Clinic proceedings 2016; (91(10)):1354-1361 doi:10.1016/j.mayocp.2016.06.027.

[The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].

Zhang CL, Feng J, Shen KN, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2016; (37(11)):942-945 doi:10.3760/cma.j.issn.0253-2727.2016.11.003.

The burden of amyloid light chain amyloidosis on health-related quality of life.

Bayliss M, McCausland KL, Guthrie SD, White MK

Orphanet journal of rare diseases 2017; (12(1)):15 doi:10.1186/s13023-016-0564-2.

Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition.

Muchtar E, Dispenzieri A, Lacy MQ, et al.

Annals of medicine 2017; (49(7)):545-551 doi:10.1080/07853890.2017.1304649.

High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study.

Mahmood S, Sovani M, Smith P, et al.

Sleep medicine 2017; (32()):191-197 doi:10.1016/j.sleep.2016.11.021.

Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

Mangione PP, Mazza G, Gilbertson JA, et al.

Journal of proteomics 2017; (165()):113-118 doi:10.1016/j.jprot.2017.06.016.

Standardisation of minimal residual disease in multiple myeloma.

Innao V, Allegra A, Russo S, et al.

European journal of cancer care 2017; (26(6)) doi:10.1111/ecc.12732.

Paraneoplastic neuropathies.

Antoine JC, Camdessanché JP

Current opinion in neurology 2017; (30(5)):513-520 doi:10.1097/WCO.0000000000000475.

Orthostatic Hypotension: A Practical Approach to Investigation and Management.

Arnold AC, Raj SR

The Canadian journal of cardiology 2017; (33(12)):1725-1728 doi:10.1016/j.cjca.2017.05.007.

A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.

Sanchorawala V, McCausland KL, White MK, et al.

British journal of haematology 2017; (179(3)):461-470 doi:10.1111/bjh.14889.

Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement.

Li T, Huang X, Cheng S, et al.

PloS one 2017; (12(9)):e0185078 doi:10.1371/journal.pone.0185078.

Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

Pun SC, Landau HJ, Riedel ER, et al.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(1)):64-70 doi:10.1016/j.echo.2017.08.017.

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Sidiqi MH, Aljama MA, Buadi FK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1323-1329 doi:10.1200/JCO.2017.76.9554.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, et al.

Blood advances 2018; (2(7)):769-776 doi:10.1182/bloodadvances.2018016782.

Epidemiology of AL amyloidosis: a real-world study using US claims data.

Quock TP, Yan T, Chang E, et al.

Blood advances 2018; (2(10)):1046-1053 doi:10.1182/bloodadvances.2018016402.

Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.

Nguyen VP, Rosenberg A, Mendelson LM, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2018; (25(3)):156-159 doi:10.1080/13506129.2018.1490261.

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.

Lilleness B, Ruberg FL, Mussinelli R, et al.

Blood 2019; (133(3)):215-223 doi:10.1182/blood-2018-06-858951.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, et al.

Nature reviews. Disease primers 2018; (4(1)):38 doi:10.1038/s41572-018-0034-3.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, et al.

Blood 2018; (132(26)):2775-2777 doi:10.1182/blood-2018-08-872226.

AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.

Manabe S, Iwasaki C, Hatano M, et al.

BMC nephrology 2018; (19(1)):337 doi:10.1186/s12882-018-1050-y.

Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.

Vaxman I, Gertz M

Acta haematologica 2019; (141(2)):93-106 doi:10.1159/000495455.

Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.

Xin Y, Hu W, Chen X, et al.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2019; (60(6)):375-383 doi:10.1016/j.hjc.2019.01.015.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, et al.

Mayo Clinic proceedings 2019; (94(3)):472-483 doi:10.1016/j.mayocp.2018.08.006.

Validation of the Boston University staging system in AL amyloidosis.

Tomlinson R, Matigian N, Mollee P

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(3)):125-127 doi:10.1080/13506129.2019.1608941.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, et al.

Haematologica 2020; (105(5)):1405-1413 doi:10.3324/haematol.2019.217695.

A Blockchain Framework for Patient-Centered Health Records and Exchange (HealthChain): Evaluation and Proof-of-Concept Study.

Hylock RH, Zeng X

Journal of medical Internet research 2019; (21(8)):e13592 doi:10.2196/13592.

A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.

Barrett CD, Dobos K, Liedtke M, et al.

JACC. Heart failure 2019; (7(11)):958-966 doi:10.1016/j.jchf.2019.07.007.

Amyloidosis in Heart Failure.

Ihne S, Morbach C, Obici L, et al.

Current heart failure reports 2019; (16(6)):285-303 doi:10.1007/s11897-019-00446-x.

Organ responses with daratumumab therapy in previously treated AL amyloidosis.

Chung A, Kaufman GP, Sidana S, et al.

Blood advances 2020; (4(3)):458-466 doi:10.1182/bloodadvances.2019000776.

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.

Roussel M, Merlini G, Chevret S, et al.

Blood 2020; (135(18)):1531-1540 doi:10.1182/blood.2019004369.

Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.

Cappelli F, Martone R, Gabriele M, et al.

The Canadian journal of cardiology 2020; (36(3)):424-431 doi:10.1016/j.cjca.2019.12.020.

Supportive Care in AL Amyloidosis.

Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

A 64-year-old woman with raccoon eyes following kidney biopsy: a case report.

Mei S, Zhao Y, Li L, et al.

BMC nephrology 2020; (21(1)):140 doi:10.1186/s12882-020-01770-4.

Cardiac Care of Patients with Cardiac Amyloidosis.

Itzhaki Ben Zadok O, Kornowski R

Acta haematologica 2020; (143(4)):343-351 doi:10.1159/000506919.

Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Kastritis E, Wechalekar A, Schönland S, et al.

British journal of haematology 2020; (190(3)):346-357 doi:10.1111/bjh.16898.

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.

Ho AH, Kinter CW, Wight J, et al.

Journal of medical case reports 2020; (14(1)):73 doi:10.1186/s13256-020-02405-w.

Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis.

Schulman A, Connors LH, Weinberg J, et al.

European journal of haematology 2020; (105(4)):495-501 doi:10.1111/ejh.13472.

Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.

Gertz MA, Dispenzieri A

JAMA 2020; (324(1)):79-89 doi:10.1001/jama.2020.5493.

Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.

Muchtar E, Gertz MA, Lacy MQ, et al.

American journal of hematology 2020; (95(11)):1280-1287 doi:10.1002/ajh.25940.

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.

Milani P, Basset M, Nuvolone M, et al.

Blood cancer journal 2020; (10(8)):90 doi:10.1038/s41408-020-00355-6.

Systemic Amyloidosis Caused by Monoclonal Immunoglobulins: Soft Tissue and Vascular Involvement.

Hoffman JE, Dempsey NG, Sanchorawala V

Hematology/oncology clinics of North America 2020; (34(6)):1099-1113 doi:10.1016/j.hoc.2020.08.004.

Supportive Care for Patients with Systemic Light Chain Amyloidosis.

Wong SW, Fogaren T

Hematology/oncology clinics of North America 2020; (34(6)):1177-1191 doi:10.1016/j.hoc.2020.08.007.

Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis.

Lee Chuy K, Drill E, Yang JC, et al.

JACC. CardioOncology 2020; (2(2)):223-231 doi:10.1016/j.jaccao.2020.05.012.

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.

Bonderman D, Pölzl G, Ablasser K, et al.

Wiener klinische Wochenschrift 2020; (132(23-24)):742-761 doi:10.1007/s00508-020-01781-z.

[Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment].

Lysenko Kozlovskaya LV, Rameev VV, Androsova TV

Terapevticheskii arkhiv 2020; (92(6)):15-22 doi:10.26442/00403660.2020.06.000666.

Neuromuscular amyloidosis: Unmasking the master of disguise.

Pinto MV, Dyck PJB, Liewluck T

Muscle & nerve 2021; (64(1)):23-36 doi:10.1002/mus.27150.

Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.

Lei C, Zhu X, Hsi DH, et al.

BMC cardiovascular disorders 2021; (21(1)):43 doi:10.1186/s12872-021-01856-3.

Use of biomarkers to diagnose and manage cardiac amyloidosis.

Castiglione V, Franzini M, Aimo A, et al.

European journal of heart failure 2021; (23(2)):217-230 doi:10.1002/ejhf.2113.

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.

Jeryczynski G, Antlanger M, Duca F, et al.

ESMO open 2021; (6(2)):100065 doi:10.1016/j.esmoop.2021.100065.

Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Stern LK, Kittleson MM

Current oncology reports 2021; (23(4)):47 doi:10.1007/s11912-021-01028-8.

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Palladini G, Milani P, Malavasi F, Merlini G

Cells 2021; (10(3)) doi:10.3390/cells10030545.

Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.

Mar E, Taylor K, Mollee P

BMJ case reports 2021; (14(4)) doi:10.1136/bcr-2020-240631.

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Hasib Sidiqi M, Gertz MA

Blood cancer journal 2021; (11(5)):90 doi:10.1038/s41408-021-00483-7.

Scanxiety: a scoping review about scan-associated anxiety.

Bui KT, Liang R, Kiely BE, et al.

BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

Muchtar E, Dispenzieri A, Gertz MA, et al.

Mayo Clinic proceedings 2021; (96(6)):1546-1577 doi:10.1016/j.mayocp.2021.03.012.

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Ravichandran S, Cohen OC, Law S, et al.

Blood cancer journal 2021; (11(6)):118 doi:10.1038/s41408-021-00510-7.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Kastritis E, Palladini G, Minnema MC, et al.

The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

Combined Subcutaneous Fat Aspirate and Skin Tru-Cut Biopsy for Amyloid Screening in Patients with Suspected Systemic Amyloidosis.

Hansen CT, Møller HEH, Rojek AM, et al.

Molecules (Basel, Switzerland) 2021; (26(12)) doi:10.3390/molecules26123649.

The Role of Autologous Stem Cell Transplantation in Amyloidosis.

Vaxman I, Dispenzieri A

Oncology (Williston Park, N.Y.) 2021; (35(8)):471-478 doi:10.46883/ONC.2021.3508.0471.

Autopsy case with concurrent transthyretin and immunoglobulin amyloidosis.

Shintani-Domoto Y, Ishino K, Naiki H, et al.

Pathology international 2022; (72(1)):65-71 doi:10.1111/pin.13179.

Light-Chain Amyloidosis With Peripheral Neuropathy as an Initial Presentation.

Qian M, Qin L, Shen K, et al.

Frontiers in neurology 2021; (12()):707134 doi:10.3389/fneur.2021.707134.

Unusual Case of Nephrotic Syndrome From Light Chain Amyloidosis in a 37-Year-Old Patient.

Salameh OK, Darok MC, Kane JA, et al.

Cureus 2021; (13(9)):e18120 doi:10.7759/cureus.18120.

AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Bianchi G, Zhang Y, Comenzo RL

JACC. CardioOncology 2021; (3(4)):467-487 doi:10.1016/j.jaccao.2021.09.003.

Dissection of the amyloid formation pathway in AL amyloidosis.

Kazman P, Absmeier RM, Engelhardt H, Buchner J

Nature communications 2021; (12(1)):6516 doi:10.1038/s41467-021-26845-0.

Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Fuchida SI, Kawamura K, Sunami K, et al.

Transplantation and cellular therapy 2022; (28(2)):76-82 doi:10.1016/j.jtct.2021.10.021.

Targeted treatments of AL and ATTR amyloidosis.

Chandrashekar P, Desai AK, Trachtenberg BH

Heart failure reviews 2022; (27(5)):1587-1603 doi:10.1007/s10741-021-10180-z.

A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.

Nakashima N, Takashio S, Morioka M, et al.

ESC heart failure 2022; (9(3)):1731-1739 doi:10.1002/ehf2.13847.

Coexistence of Positive 99mTc-DPD Scintigraphy and Monoclonal Gammopathy: A Frequent Challenge.

Roteta Unceta-Barrenechea A, Melero Polo J, Andrés Gracia A, et al.

Acta Cardiologica Sinica 2022; (38(2)):169-174 doi:10.6515/ACS.202203_38(2).20210927A.

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.

Maurer MS, Dunnmon P, Fontana M, et al.

Circulation. Heart failure 2022; (15(6)):e009038 doi:10.1161/CIRCHEARTFAILURE.121.009038.

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

Blair HA

Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.

The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement.

Zhao L, Ren G, Guo J, et al.

Annals of medicine 2022; (54(1)):1226-1232 doi:10.1080/07853890.2022.2069281.

Daratumumab in AL amyloidosis.

Wechalekar AD, Sanchorawala V

Blood 2022; (140(22)):2317-2322 doi:10.1182/blood.2021014613.

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

Yimer H, Melear J, Faber E, et al.

Leukemia & lymphoma 2022; (63(10)):2383-2392 doi:10.1080/10428194.2022.2076847.

Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective.

Bomsztyk J, Khwaja J, Wechalekar AD

Expert review of hematology 2022; (15(9)):781-788 doi:10.1080/17474086.2022.2115353.

Amyloidosis of the Heart and Kidney.

Adrogue HE

Methodist DeBakey cardiovascular journal 2022; (18(4)):27-33 doi:10.14797/mdcvj.1150.

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.

Martinez-Naharro A, Patel R, Kotecha T, et al.

European heart journal 2022; (43(45)):4722-4735 doi:10.1093/eurheartj/ehac363.

Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.

Kim HR, Yoon SE, Kim D, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(2)):97-103 doi:10.1016/j.clml.2022.10.010.

Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income country.

Szor RS, Fernandes F, Lino AMM, et al.

Orphanet journal of rare diseases 2022; (17(1)):425 doi:10.1186/s13023-022-02584-3.

Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.

Kastritis E, Misra A, Gurskyte L, et al.

Hematology (Amsterdam, Netherlands) 2023; (28(1)):2157581 doi:10.1080/16078454.2022.2157581.

Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.

Zanwar S, Gertz MA, Muchtar E

Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(1)):83-90 doi:10.6004/jnccn.2022.7077.

Do Not Ignore Those Raccoon Eyes; They May Indicate Lethal AL Amyloidosis.

Sapkota S, Kuehl S, Pulluri B

Case reports in oncology 2022; (15(3)):1039-1048 doi:10.1159/000527169.

Diagnosis and Treatment of AL Amyloidosis.

Palladini G, Milani P

Drugs 2023; (83(3)):203-216 doi:10.1007/s40265-022-01830-z.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS.

Idowu A, Tung L, Chu C, et al.

European journal of case reports in internal medicine 2023; (10(2)):003768 doi:10.12890/2023_003768.

Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis.

Lee T, Park CJ, Kim M, et al.

Blood research 2023; (58(1)):71-76 doi:10.5045/br.2023.2022232.

Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.

Xie W, Wang Q, Zhou F, et al.

International journal of hematology 2023; (118(2)):231-241 doi:10.1007/s12185-023-03617-8.

Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls.

De Michieli L, Sinigiani G, De Gaspari M, et al.

Internal and emergency medicine 2023; (18(7)):1879-1886 doi:10.1007/s11739-023-03335-3.

Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.

Wees I, Hendren NS, Kaur G, et al.

Current heart failure reports 2023; (20(5)):350-357 doi:10.1007/s11897-023-00616-y.

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.

Oubari S, Hegenbart U, Schoder R, et al.

Haematologica 2024; (109(1)):220-230 doi:10.3324/haematol.2023.283325.

Cardiovascular toxicity from therapies for light chain amyloidosis.

Morfino P, Aimo A, Castiglione V, et al.

Frontiers in cardiovascular medicine 2023; (10()):1212983 doi:10.3389/fcvm.2023.1212983.

Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.

Mauermann ML, Clarke JO, Litchy WJ, et al.

Advances in therapy 2023; (40(11)):4695-4710 doi:10.1007/s12325-023-02637-4.

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).

Brito D, Albrecht FC, de Arenaza DP, et al.

Global heart 2023; (18(1)):59 doi:10.5334/gh.1262.

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2024; (99(2)):309-324 doi:10.1002/ajh.27177.

Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.

Lacouture Fierro JA, Ribero Vargas DA, Sánchez Cano J, et al.

Colombia medica (Cali, Colombia) 2023; (54(3)):e2025667 doi:10.25100/cm.v54i3.5667.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review.

Javed N, Singh K, Shirah J, Vittorio TJ

Current cardiology reviews 2024; (20(4)):e080324227805 doi:10.2174/011573403X280737240221060630.

Risk stratification in multiple myeloma: Are we there yet?

Mohan M, Schinke C

British journal of haematology 2024; (204(5)):1585-1587 doi:10.1111/bjh.19416.

18 F-FDG Uptake in Pancreatic AL Amyloidosis Associated With Multiple Myeloma.

Kaida H, Chikugo T, Tanaka H, Ishii K

Clinical nuclear medicine 2024; (49(8)):781-783 doi:10.1097/RLU.0000000000005296.

AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

Tan M, Chen Y, Ooi M, et al.

Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.

Clerc OF, Cuddy SAM, Jerosch-Herold M, et al.

JACC. Cardiovascular imaging 2024; (17(11)):1271-1286 doi:10.1016/j.jcmg.2024.05.004.

Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study.

Shen SP, Hou HA, Huang KC, et al.

Scientific reports 2024; (14(1)):16915 doi:10.1038/s41598-024-65654-5.

Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis.

Leung N, Comenzo R, Gillmore J, et al.

Kidney international reports 2024; (9(7)):1986-1994 doi:10.1016/j.ekir.2024.03.033.

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

Muchtar E, Wisniowski B, Geyer S, et al.

JAMA oncology 2024; (10(10)):1362-1369 doi:10.1001/jamaoncol.2024.2629.

Successes in translation.

Westermark P, Merlini G

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(3)):159-167 doi:10.1080/13506129.2024.2387163.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

Diagnosing AL and ATTR Amyloid Cardiomyopathy: A Multidisciplinary Approach.

Aus dem Siepen F, Hansen T

Journal of clinical medicine 2024; (13(19)) doi:10.3390/jcm13195873.

Warning values of serum total kappa/lambda ratio for M-proteinemia.

Lu J, Zhu Y, Huang H, et al.

BMC immunology 2024; (25(1)):73 doi:10.1186/s12865-024-00664-6.

Primary systemic amyloidosis: A brief overview.

Hughes MS, Lentzsch S

Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.

Xu CY, Guan A, Zhang L, et al.

JACC. Asia 2025; (5(1)):74-84 doi:10.1016/j.jacasi.2024.10.005.

Periorbital Purpura: A Key Finding in Identifying Hematological Disorders.

Ono R, Iwahana T, Aoki K, et al.

Clinical case reports 2025; (13(2)):e70237 doi:10.1002/ccr3.70237.

The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment.

Allinovi M, Trivioli G, Gaudio C, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (40(10)):1826-1837 doi:10.1093/ndt/gfaf042.

Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens.

Saunders B, Theodorakakou F, Fotiou D, et al.

Blood advances 2025; (9(15)):3771-3779 doi:10.1182/bloodadvances.2024015528.

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.

Yohannan B, Rees M, Gertz MA, et al.

Blood neoplasia 2025; (2(2)):100092 doi:10.1016/j.bneo.2025.100092.

Characterization, outcome and identification of prognostic factors for patients with systemic immunoglobulin lightchain amyloidosis requiring dialysis prior to initial anticlonal therapy.

Sester LS, Milani P, Theodorakakou F, et al.

Haematologica 2025; (110(12)):3042-3052 doi:10.3324/haematol.2025.287434.

From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.

Muchtar E, Dispenzieri A, Buadi FK, et al.

Blood advances 2025; (9(16)):4311-4316 doi:10.1182/bloodadvances.2025016586.

Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.

Laires PA, Fang S, Evans J, et al.

Scientific reports 2025; (15(1)):25149 doi:10.1038/s41598-025-09498-7.

Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.

Benz DC, Clerc OF, Cuddy SAM, et al.

JACC. Cardiovascular imaging 2025; (18(12)):1363-1374 doi:10.1016/j.jcmg.2025.07.017.

What Cardiologists Should Know About Amyloidosis.

Alashqar R, Alkhatib A, Abdallah AW, et al.

Journal of clinical medicine 2025; (14(18)) doi:10.3390/jcm14186668.

Multisystem Light Chain Amyloidosis: Diagnostic and Therapeutic Challenges.

Lin HZ, Ko KKK, Kandaswamy T, et al.

Cureus 2025; (17(8)):e91334 doi:10.7759/cureus.91334.

Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations.

Tang MJ, Tay TY, Gibbs S, Niewiadomski O

Journal of gastroenterology and hepatology 2025; (40(12)):2842-2856 doi:10.1111/jgh.70083.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.

Hu H, Wang Y, Xu M

Pharmaceutical research 2025; doi:10.1007/s11095-025-03965-6.

"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

Derry-Vick H, Prigerson HG, Hahne J, et al.

Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients.

Burke NJ, Mendelson LM, Joshi T, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; 1-9 doi:10.1080/13506129.2025.2606847.

Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.

Bazarbachi AH, Zanwar S, Hegenbart U, et al.

HemaSphere 2025; (9(12)):e70276 doi:10.1002/hem3.70276.

Prognostic Impact of Bone Marrow Plasma Cell Percentage in Patients With Systemic Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis.

Nie ZY, Aihemaiti Y, Meng FQ, et al.

European journal of haematology 2026; (116(6)):826-834 doi:10.1111/ejh.70138.

Hepatic-Predominant Immunoglobulin G Lambda Light Chain Amyloidosis Associated With Multiple Myeloma: A Report of an Exceptionally Rare Case.

Jesus G, Soares I, Silva AS, et al.

Cureus 2026; (18(1)):e101793 doi:10.7759/cureus.101793.